To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol

Inclusion Criteria: * Female and male subjects aged 18 - 65 years * Exercise induced asthma with reversible airway obstruction: twice proven EIA defined as maximum decrease in FEV1 against the baseline value of at least 20% (first test results can be obtained during the last 12 months) * Baseline FEV1 before challenge must be \> or = 70% of the predicted FEV1 Exclusion Criteria: Safety concerns: * Subjects with hypersensitivity to DSCG, reproterol, menthol, peppermint or other excipients of the study medication * Pregnancy, breast-feeding or planned pregnancy during the study. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. \<1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner * Subjects with an asthma exacerbation within 4 weeks prior to the study start. Asthma exacerbation defined as use of oral (systemic) glucocorticosteroids, unscheduled consultation of a medic due to asthma, hospitalisation, or additional treatment of asthma with antibiotics * Eosinophilic pneumonia * Clinically significant cardiovascular diseases (e.g. cardiac infarction, cardiac dysrhythmia, hypertrophic obstructive cardiomyopathy, coronary heart disease…) * Resting blood pressure over 140/90 mmHg * Diastolic blood pressure after treadmill-test over 120 mmHg * Malignancies including phaeochromocytoma within the last 5 years * Severe hyperthyreosis, thyreotoxicosis, instable diabetes mellitus Lack of suitability for the trial: * Subjects with seasonal asthma during their asthma season * Infectious disease of the upper airways within 2 weeks prior to the study and within 4 weeks prior to study in case of use of antibiotics * Relevant respiratory disorder other than asthma * Clinically significant renal, endocrine, haematological, hepatic, immunological, gastrointestinal, neurological, or psychiatric diseases * Any chronic disease which might influence absorption, metabolism, or excretion of the trial substances * Change of inhalative glucocorticosteroid dosage and / or antiasthmatic controller therapy within the last 4 weeks prior to or during the study * Concomitant systemic treatment with glucocorticosteroids * Concomitant treatment with any ß-antagonistic drug * Need of rescue medication within 15 min after challenge * Concomitant therapy with antidepressants or neuroleptics * Drug or alcohol abuse which would interfere with the subjects proper completion of the protocol assignment and mentally handicapped subjects * Smokers within the last 6 months or smoking history \> 10 pack-years (a pack-year is 20 cigarettes per day for one year or equivalent) * Exposure to another investigational agent within the last 4 weeks prior to this one or during this study * Non-cooperative subjects not able to understand the instructions for use of the devices Administrative reasons: * Lack of ability or willingness to give informed consent * Lack of willingness to have personal study related data collected, archived or transmitted according to protocol * Anticipated non-availability for study visits / procedures * Personnel involved in the planning or conduct of the study